Movfor COVID-19 Drugs Started To Be Marketed

PHOTO VIA BETWEEN

JAKARTA - PT Kalbe Farma Tbk ("Kalbe") together with PT Amarox Global Pharma ("Amarox") have started marketing Movfor (Molnupiravir), the newest anti-viral drug that can be used in the treatment of COVID-19.

The drug is intended for therapy in COVID-19 patients aged over 18 years with mild and moderate symptoms, who do not require oxygen administration and have an increased risk of developing severe COVID-19 infection based on the latest edition of the COVID-19 Management Guidelines in Indonesia.

Molnupiravir is a new anti-viral drug that has received an emergency use authorization, Emergency Use Authorization, from the United States FDA and from the Indonesian National Food and Drug Administration (BPOM) for the treatment of COVID-19.

Meanwhile, Movfor is the first Molnupiravir product to obtain an emergency use permit from the POM in Indonesia and was officially launched in Indonesia on February 15, 2022 by PT Amarox Global Pharma.

"Based on the results of the phase 3 clinical trial, Molnupiravir is effective against the currently existing SARS-CoV-2 virus variant and has the potential to inhibit infection of the Omicron SARS-CoV-2 variant with an RT-PCR viral clearance result of 100 percent on day 5," said Dr. Sandeep Sur, General Manager of PT Amarox Pharma Global in a press release quoted by Antara, Friday, February 18.

He added, Mofvor has been marketed and used to treat COVID-19 patients in India and in several ASEAN countries.

Mulia Lie, Director of PT Kalbe Farma Tbk. said Kalbe currently has national marketing and distribution infrastructure capabilities with strong access to health workers, hospitals and pharmacies.

With the support of 76 distribution branches in 34 provinces, it is expected to be able to accelerate wider access and availability of drugs for COVID-19 therapy throughout Indonesia.

“Previously, Kalbe has collaborated with Amarox as the main partner in the marketing and distribution of COVID-19 antiviral drugs. The Movfor (Molnupiravir) drug marketing collaboration is a continuation of other COVID-19 drug collaborations, namely Covifor (Remdesivir) and Fluvir (Oseltamivir). These three antiviral drugs will help strengthen the availability of COVID-19 drugs for the community," said Mulia Lie.